TABLE 3.

Clinical features of patients and characteristics of A. baumannii isolates with bla_SIM-1 cassette-carrying class 1 integrons

Patient no.	Isolatea	Age (yrs)/sex	Underlying disease	Hospital ward	Days since admissionb	Previous antimicrobial therapy (days)c	Specimen/ diagnosisc	MIC (μg/ml)c												PFGE pattern
								SAM	PIP	CTX	CAZ	FEP	ATM	IPM	MEM	GEN	TOB	AMK	CIP
1	03/9/T104	9/F	Cerebral palsy	Intensive care unit	30	MEM (12), ATM (9), FEP (5)	Sputum/ pneumonia	16	64	>256	>256	64	128	8	16	16	16	128	0.5	A1
2	04/5/U2266	66/F	Hypothyroidism, osteoporosis, hypertension	Outpatient	NA	ROX (10)	Urine/UTI	16	64	>256	>256	64	128	8	16	16	16	128	0.5	A1
3	04/8/U1575	64/M	Herniated lumbar disc	Internal medicine	9	FMX (7)	Urine/UTI	16	32	>256	>256	64	128	16	16	16	16	128	0.5	A2
4	04/11/U1817	45/M	Intracranial hemorrhage	Internal medicine	11	ISP (8), CTX (7), CFM (4)	Urine/UTI	16	32	>256	>256	64	128	8	16	16	16	128	0.5	A2
5	04/12/U575	13/M	Chronic myelogenous leukemia	Pediatrics	4	None	Urine/UTI	16	128	>256	>256	128	128	16	16	16	16	128	0.5	B1
6	04/12/U837	5/M	Acute lymphocytic leukemia	Pediatrics	3	AMC (4)	Urine/UTI	16	256	>256	>256	64	128	8	16	16	16	128	0.5	B1
7	04/12/U1398	3/M	Acute myelogenous leukemia	Pediatrics	3	SXT (3), AMC (2), ISP (2)	Urine/UTI	16	128	>256	>256	128	128	8	16	16	16	64	0.5	B2

^aThe first two numbers, separated by a slash, indicate the year and month of isolation, respectively.

^bDays between admission and the isolation of SIM-1-producing A. baumannii.

^cAbbreviations: SAM, ampicillin-sulbactam; PIP, piperacillin; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam; IPM, imipenem; MEM, meropenem; GEN, gentamicin; TOB, tobramycin; AMK, amikacin; CIP, ciprofloxacin; ROX, roxithromycin; FMX, flomoxef; ISP, isepamycin; CFM, cefixime; AMC, amoxicillin-clavulanate; SXT, trimethoprim-sulfamethoxazole; NA, not applicable; UTI, urinary tract infection.